Here's Why Novo Nordisk Just Paid $2.1 Billion For Zaltenibart (NYSE:NVO)

Novo Nordisk A/S ( NVO ) has just shelled out a whopping $2.1 billion, and it's not for the acquisition of a whole company. It's actually just for one compound, Zaltenibart. Now, as you would have guessed, Novo must seeI hold a Master’s degree in Cell Biology and began my career working for several years as a lab technician in a drug discovery clinic, where I gained extensive hands-on experience in cell culture, assay development, and therapeutic research. That scientific foundation gave me an appreciation ...